Envigo Facilities Earn AAALAC Accreditation
News Jul 20, 2016
Envigo has announced that its breeding facilities in Bresso, Italy and Wyton, UK have been granted full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. This news follows the accreditation of Envigo’s Horst, Netherlands facility earlier this year and demonstrates continued progress towards the company’s goal to have all sites accredited by AAALAC. To support these achievements, Envigo has made targeted investments in people, process and facilities that will help to ensure the quality of Envigo research models.
Recent developments at the Bresso site in Italy illustrate the quality improvement programs now in place throughout Envigo breeding facilities. The almost 3,000 m² ISO:9001-2008 certified site consists of a contract breeding services area, an assisted reproductive technologies laboratory, and a health monitoring laboratory for microbiology, immunology and molecular biology testing. The facility also has quarantine and embryo transfer areas and a research space for customers. The contract breeding services area has recently been expanded and new laboratory management software has been installed.
Improvements have been made to the health monitoring laboratory which now offers fully validated PCR and immunology tests with the data managed through a recently validated upgraded LIMS system. Dr. Paul Brooker, President of Contract Research and Research and Models Services in Europe commented: “The AAALAC accreditation of Wyton and Bresso is great news and demonstrates the high standards we set for animal welfare and quality at Envigo. This is the third accreditation for our European breeding facilities in four months and is testimony to the efforts and commitment of our professional staff, which has now been validated by AAALAC, a great honor for us all.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018